association

Full identifier: http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#association

Assigned to 1 class:

Minted in Nanopublication

 RADf4hBIig comment approve/disapprove edit as derived nanopublication create new with same template

This is the identifier for this whole nanopublication. http://purl.org/np/RADf4hBIig... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-06-12T13:26:08.716+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RADf4hBIig... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAManV5GZI... RAManV5GZI .
This is the identifier for this whole nanopublication. http://purl.org/np/RADf4hBIig... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RADf4hBIig... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .

References

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T11:26:08.716Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
farydak a histone deacetylase inhibitor in combination with bortezomib and dexamethasone is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior regimens including bortezomib and an immunomodulatory agent this indication is approved under accelerated approval based on progression free survival see clinical studies 14 1 farydak a histone deacetylase inhibitor in combination with bortezomib and dexamethasone is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior regimens including bortezomib and an immunomodulatory agent this indication is approved under accelerated approval based on progression free survival continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials 1
Leoni Bücken
2021-06-12T11:26:08.716Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T11:26:08.716Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T11:26:08.716Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T11:26:08.716Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T11:26:08.716Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T11:26:08.716Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-12T11:26:08.716Z

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)